source
- Roche partners with China's Simcere Zaiming on $1.5 billion T-cell engager for B-cell diseasesRoche announced a licensing agreement with Simcere Zaiming, a subsidiary of China's Simcere Pharmaceutical Group, to develop a trispecific T-cell engager called SIM0660. The deal includes an upfro…
- GSK to begin Phase 3 trial of mRNA seasonal flu vaccine after strong Phase 2 resultsGSK announced it will start a Phase 3 study of its mRNA vaccine targeting seasonal influenza. The move follows Phase 2 data that showed the candidate produced higher immune responses than traditio…